Abstracts tagged "Administrative Data"

Abstract Number: 0807 • ACR Convergence 2023
Inferring Disease Activity Scores and Low Disease Activity at Registry Visits Based on Structured and Narrative Data from Electronic Health Records
David Cheng¹, Dana Weisenfeld², Kumar Dahal², Qing Liu², Vidul Ayakulangara Panickan³, Mary Jeffway², Thany Seyok², Gregory McDermott², Michael Weinblatt⁴, Nancy Shadick⁵, Tianxi Cai⁶ and Katherine Liao², ¹Massachusetts General Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Harvard Medical School, Boston, MA, ⁴Harvard Medical School, Waban, MA, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Harvard T.H. Chan School of Public Health, Boston, MA
Background/Purpose: Real-world data including electronic health records (EHRs) are a promising resource for learning to optimize treatment strategies for rheumatoid arthritis (RA). A major challenge…
Abstract Number: 1275 • ACR Convergence 2023
Prevalence of Frailty Among Individuals Living with Rheumatoid Arthritis: A Population-based Cohort Study
Alexandra Legge¹ and Diane Lacaille², ¹Dalhousie University, Halifax, NS, Canada, ²Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Studies have demonstrated a link between frailty and chronic inflammation, raising the question of whether chronic inflammatory diseases like rheumatoid arthritis (RA) may be…
Abstract Number: 2522 • ACR Convergence 2023
Diabetes Mellitus Impacts Primary Total Hip Arthroplasty Outcomes: A National Cohort Study
Sumanth Chandrupatla¹, Kranti Rumalla² and Jasvinder Singh¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Northwestern School of Medicine, Chicago, IL
Background/Purpose: Primary total hip arthroplasty (THA) patients often have concomitant medical comorbidities. This study aims to identify the impact of diabetes mellitus (DM) on inpatient…
Abstract Number: 0811 • ACR Convergence 2023
Comparative Effectiveness of Sodium-glucose cotransporter-2 Inhibitors for Recurrent Gout Flares and Gout-primary Emergency Department Visits and Hospitalizations: A General Population Cohort Study
Natalie McCormick¹, Chio Yokose², Jie Wei³, Na Lu⁴, Deborah Wexler¹, Mary De Vera⁵, J. Antonio Avina-Zubieta⁴, Yuqing Zhang⁶ and Hyon K. Choi⁷, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Waltham, MA, ³Health Management Center, Xiangya Hospital Central South University, Changsha, China, ⁴Arthritis Research Canada, Vancouver, BC, Canada, ⁵University of British Columbia, Vancouver, BC, Canada, ⁶Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, ⁷Massachusetts General Hospital and Harvard Medical School, Lexington, MA
Background/Purpose: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) lower serum urate (primary prevention); however, whether this translates into preventing recurrent flares among gout patients (secondary prevention) and gout-primary…
Abstract Number: 1291 • ACR Convergence 2023
Risk Factors for Major Adverse Cardiovascular Events and Malignancies in Patients with Rheumatoid Arthritis in a Real-World Setting in Japan
Toshitaka Hirano¹, Naonobu Sugiyama², Masato Hoshi¹, Joo-Young Jo³, Kichul Shin⁴ and Kunihiro Yamaoka⁵, ¹Pfizer Japan Inc, Tokyo, Japan, ²Pfizer Japan Inc, Japan, Japan, ³Pfizer Pharmaceuticals Korea Ltd, Seoul, South Korea, ⁴Seoul Metropolitan Government- Seoul National University Boramae Medical Center, Seoul, South Korea, ⁵Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Sagamihara, Japan
Background/Purpose: Patients (pts) with RA are at an increased risk of major adverse cardiovascular events (MACE) and malignancies vs the general population.1,2 However, risk factors…
Abstract Number: 2528 • ACR Convergence 2023
Current Trends in the Risk of Subsequent Fracture After Initial Fracture, and Post-Fracture Treatment Among Commercially Insured Postmenopausal Women in the United States
Min Kim¹, Vanessa C. Brunetti¹, Felicia Cosman², Jeffrey Curtis³, E Michael Lewiecki⁴, Matthew Phelan⁵, Peter Samai⁵, Michele McDermott¹, Tzu-Chieh Lin¹, M Alan Brookhart⁶ and Kathleen Hurwitz⁵, ¹Amgen, Inc., Thousand Oaks, CA, ²Columbia University, New York, NY, ³University of Alabama at Birmingham, Birmingham, AL, ⁴New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, ⁵Target RWE, Durham, NC, ⁶Department of Population Health Sciences, Duke University, Durham, NC
Background/Purpose: Recent studies suggest that post-fracture pharmacologic management has been declining in the U.S. despite an increase in the burden of osteoporosis (OP). In light…
Abstract Number: 0833 • ACR Convergence 2023
Machine Learning Detected Healthcare Encounter Patterns Leading to Diagnosis of Juvenile Arthritis in a Population-Based Canadian Cohort
Lily Lim, Connor Hryhoruk, Ruth Ann Marrie, Christine Peschken, Carson Leung and Lisa Lix, University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Increases in health care visits precede the first diagnosis code for inflammatory arthritis (IA) by an average of 5 years in adults, but it…
Abstract Number: 1324 • ACR Convergence 2023
Previous History of Serious Infection Is Associated with the Use of IL-6 Inhibitors in Rheumatoid Arthritis in Wales, UK
Roxanne Cooksey¹ and Ernest Choy², ¹Cardiff University, Cardiff, United Kingdom, ²Section of Rheumatology, Cardiff University, Cardiff, United Kingdom
Background/Purpose: Biologic therapy has revolutionised the treatment of rheumatoid arthritis (RA). Randomised control trials have shown that IL-6 inhibitors are superior to adalimumab, a TNF…
Abstract Number: 2529 • ACR Convergence 2023
Comparative Effectiveness of Denosumab versus Zoledronic Acid Among Postmenopausal Women with Osteoporosis in the U.S. Medicare Program
Jeffrey R Curtis¹, Tarun Arora², Ye Liu³, Vanessa C. Brunetti⁴, Tzu-Chieh Lin⁴, Leslie Spangler⁴, Robert K. Stad⁴, Michele McDermott⁴, Brian D. Bradbury⁴ and Min Kim⁴, ¹Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL, ²Foundation for Advancing Science, Technology, Education, and Research, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Amgen, Inc., Thousand Oaks, CA
Background/Purpose: Although clinical trials have shown that denosumab (Dmab) significantly increases bone mineral density at key skeletal sites more than zoledronic acid (ZA), evidence from…
Abstract Number: 001 • 2023 Pediatric Rheumatology Symposium
Serious Infections Among Children with Systemic Lupus Erythematosus in the Pediatric Health Information System
Jordan Roberts, Anna Faino, Mersine Bryan, Jonathan Cogen and Esi Morgan, Seattle Children's Hospital, Seattle, WA
Background/Purpose: High rates of serious infection have beenreported in pediatric systemic lupus erythematosus (pSLE), but modern care practices including pneumococcal vaccination, changing corticosteroid use, and…
Abstract Number: 131 • 2023 Pediatric Rheumatology Symposium
Improving Methotrexate Documentation in Electronic Health Records – a Quality Improvement Initiative
Jayne MacMahon¹, Jeanine McColl², Alaa Al-Shehab¹, Deborah Levy³, Ronald laxer¹ and Shirley Tse¹, ¹University of Toronto, The Hospital for Sick Children, Toronto, ON, Canada, ²University of Alberta, Edmonton, AB, Canada, ³The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Prescribing methotrexate,is common practice in rheumatology. Appropriate medication counselling and documentation is important. In our province, as per thephysician regulatory body the College of…
Abstract Number: 0075 • ACR Convergence 2022
Real-World Treatment Patterns Among Patients with Connective Tissue Disorder–Related Pulmonary Arterial Hypertension in the United States: A Retrospective Claims-Based Analysis
Yuen Tsang¹, Marjolaine Gauthier-Loiselle², Vienica Funtanilla³, Hayley Germack³, Ameur Manceur⁴, Stephanie Liu², Martin Cloutier², Patrick Lefebvre² and Sumeet Panjabi⁵, ¹Janssen Scientific Affairs, LLC., Sacramento, CA, ²Analysis Group, Inc., Montréal, QC, Canada, ³Janssen Scientific Affairs, LLC, Titusville, NJ, ⁴Analysis Group, Inc, Boston, MA, ⁵Analysis Group, Inc., Titusville, NB, Canada
Background/Purpose: Connective tissue disorders (CTDs) are the most frequent diseases associated with pulmonary arterial hypertension (PAH), accounting for 11% – 28% of PAH cases. A…
Abstract Number: 0959 • ACR Convergence 2022
Assessing the Association Between Hydroxychloroquine and Preeclampsia Risk in SLE Pregnancies Using Administrative Claims Data
Amadeia Rector¹, Ivana Marić², Yashaar Chaichian³, Eliza Chakravarty⁴, Miranda Cantu⁵, Michael Weisman⁶, Gary Shaw⁷, Maurice Druzin⁷ and Julia Simard¹, ¹Stanford University School of Medicine, Palo Alto, CA, ²Stanford University, Stanford, ³Stanford University, Stanford, CA, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Global Lupus Support Group, Portage, MI, ⁶Adjunct Professor of Medicine, Stanford University; Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁷Stanford University School of Medicine, Palo Alto
Background/Purpose: Preeclampsia risk is higher among pregnancies in patients with systemic lupus erythematosus (SLE). Hydroxychloroquine (HCQ), a common first-line treatment, is encouraged in SLE pregnancies…
Abstract Number: 2216 • ACR Convergence 2022
JAK Inhibitors and Risk of Cancer
Amandine Gouverneur¹, Jérôme Avouac², Clément Prati³, Jean-Luc Cracowski⁴, Thierry schaeverbeke⁵, Antoine Pariente¹ and Marie-Elise Truchetet⁵, ¹Université de Bordeaux, Bordeaux, France, ²University of Paris, Paris, France, ³Service de rhumatologie, CHU de Besançon, Besançon, France, ⁴Université de Grenoble, Grenoble, France, ⁵CHU de Bordeaux, Bordeaux, France
Background/Purpose: Recent concerns have been raised about potential increase of cancer risk under JAK inhibitors (JAKi) especially tofacitinib. Discrepant findings have been given by randomized…
Abstract Number: 0076 • ACR Convergence 2022
Real World Rheumatology Practice of Biologic Monotherapy for the Treatment of Patients with Rheumatoid Arthritis: A Four-year Cohort Study Using a National Claims Database
Ko-Jen Li¹, Kuo-Cherh Huang², Chia-Cheng Lin³ and Chia-Li Chang², ¹National Taiwan University Hospital, Taipei, Taiwan, ²Taipei Medical University, Taipei, Taiwan, ³Chugai Pharma Taiwan Ltd., Taipei, Taiwan
Background/Purpose: There is a growing concern over the rise of polypharmacy, arguably one of the most pressing prescribing challenges. The option of biologic monotherapy is…

« Previous Page
1
…
4
5
6
7
8
…
13
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].